DE69019293D1 - Naphthyloxazolidon-Derivate. - Google Patents

Naphthyloxazolidon-Derivate.

Info

Publication number
DE69019293D1
DE69019293D1 DE69019293T DE69019293T DE69019293D1 DE 69019293 D1 DE69019293 D1 DE 69019293D1 DE 69019293 T DE69019293 T DE 69019293T DE 69019293 T DE69019293 T DE 69019293T DE 69019293 D1 DE69019293 D1 DE 69019293D1
Authority
DE
Germany
Prior art keywords
group
hydroxy
amino
derivative
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69019293T
Other languages
English (en)
Other versions
DE69019293T2 (de
Inventor
Hideo Nakai
Koichiro Yamada
Sumihiro Nomura
Mamoru Matsumoto
Hiroshi Iwata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Seiyaku Co Ltd
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Application granted granted Critical
Publication of DE69019293D1 publication Critical patent/DE69019293D1/de
Publication of DE69019293T2 publication Critical patent/DE69019293T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/84—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems
    • C07C215/86—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems being formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/94—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69019293T 1989-10-26 1990-10-19 Naphthyloxazolidon-Derivate. Expired - Fee Related DE69019293T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27930589 1989-10-26

Publications (2)

Publication Number Publication Date
DE69019293D1 true DE69019293D1 (de) 1995-06-14
DE69019293T2 DE69019293T2 (de) 1995-09-07

Family

ID=17609315

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69019293T Expired - Fee Related DE69019293T2 (de) 1989-10-26 1990-10-19 Naphthyloxazolidon-Derivate.

Country Status (10)

Country Link
US (2) US5182296A (de)
EP (1) EP0425209B1 (de)
JP (1) JP2601008B2 (de)
KR (1) KR0128288B1 (de)
AT (1) ATE122344T1 (de)
CA (1) CA2028440C (de)
DE (1) DE69019293T2 (de)
DK (1) DK0425209T3 (de)
ES (1) ES2074544T3 (de)
HK (1) HK99197A (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182296A (en) * 1989-10-26 1993-01-26 Tanabe Seiyaky Co., Ltd. Naphthyloxazolidone derivatives
JPH0559022A (ja) * 1991-09-05 1993-03-09 Nippon Paint Co Ltd ５位に置換基を有する２−オキサゾリジノン化合物
JP3042156B2 (ja) * 1992-02-20 2000-05-15 田辺製薬株式会社 ナフタレン誘導体、その製法及びその合成中間体
TW286317B (de) * 1993-12-13 1996-09-21 Hoffmann La Roche
DE4425609A1 (de) * 1994-07-20 1996-01-25 Bayer Ag Benzofuranyl- und Benzothienyloxazolidinone
CA2223011C (en) * 1995-06-02 2007-01-09 Synthelabo Oxazolidinone derivatives, their preparation and therapeutical use
FR2734820B1 (fr) * 1995-06-02 1997-07-11 Synthelabo Derives de 3-(1,2-benzisoxazol-3-yl)oxazolidin-2-one, leur preparation et leur application en therapeutique
FR2734821B1 (fr) * 1995-06-02 1997-07-11 Synthelabo Derives de 5-methoxymethyl-3-(1,2-benzisoxazol-3-yl) oxazolidin-2-one, leur preparation et leur application en therapeutique
US5919792A (en) * 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
JP3865450B2 (ja) * 1997-02-14 2007-01-10 田辺製薬株式会社 パーキンソニズム治療剤
DE19723498C1 (de) * 1997-06-05 1998-07-09 Goldschmidt Ag Th 2-Oxazolidinongruppen enthaltende Organosilane und Organopolysiloxane, deren Verwendung als grenzflächenaktive Substanzen sowie deren Verwendung zur Herstellung Amino- oder Carbamidgruppen enthaldender Organosilane und Organopolysiloxane
DE19730847A1 (de) * 1997-07-18 1999-01-28 Bayer Ag Tricyclisch substituierte Oxazolidinone
NZ504372A (en) 1997-11-07 2002-12-20 Upjohn Co Process to produce N-[3-fluoro-4(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinones
EP1008590B1 (de) 1998-12-07 2006-10-11 Takasago International Corporation Verfahren zur Herstellung von optisch aktiven Oxazolidinonderivate
US6558475B1 (en) 2000-04-10 2003-05-06 International Business Machines Corporation Process for cleaning a workpiece using supercritical carbon dioxide
WO2002032857A1 (en) 2000-10-17 2002-04-25 Pharmacia & Upjohn Company Methods of producing oxazolidinone compounds
KR100496049B1 (ko) * 2001-12-31 2005-06-17 주식회사 디피아이 열경화성 우레탄 변성 폴리에스테르 수지 조성물
CN104262280B (zh) * 2014-09-22 2016-07-20 山东华生化学股份有限公司 一种利奈唑酮的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB753987A (en) * 1953-01-29 1956-08-01 Sandoz Ltd Monoazodyestuffs, metallised and unmetallised, and processes for their preparation
CH372056A (fr) * 1958-11-10 1963-09-30 Om Lab Sa Procédé de préparation d'éthers de la 5-hydroxyméthyl-2-oxazolidone
CH382167A (fr) * 1959-06-11 1964-09-30 Om Lab Sa Procédé de préparation d'éthers de la 5-hydroxyméthyl-2-oxazolidone
NL133317C (de) * 1966-06-24 1900-01-01
FR1530783A (fr) * 1966-06-24 1968-06-28 Henkel & Cie Gmbh Procédé de préparation d'oxazolidones substituées
GB1180089A (en) * 1967-10-20 1970-02-04 Delalande Sa Acetylenic Derivatives of 2-Oxazolidinones and processes of preparation
FR1602544A (en) * 1968-10-29 1970-12-21 Acetylenic 2-oxazolidinones
GB1250538A (de) * 1969-03-18 1971-10-20
US3776943A (en) * 1970-09-25 1973-12-04 Merck & Co Inc 4-(and 5-)loweralkoxycarbonylamino-1-naphthyl-n-loweralkylcarbamates
SU537997A1 (ru) * 1973-06-15 1976-12-05 Научно-Исследовательский Сектор Каунасского Политехнического Института Им.Антанаса Снечкуса Способ получени натриевой соли -диоксипропил-1-амино-4/5-или 6-/-нафталинсульфокислоты
JPS5116661A (en) * 1974-08-02 1976-02-10 Sagami Chem Res 55 hidorokishimechiru 22 okisazorijinonno seizoho
US4069240A (en) * 1975-09-04 1978-01-17 Uniroyal, Inc. Nuclear hydrogenation of n-aryl carbamates
JPS5283533A (en) * 1976-01-01 1977-07-12 Kyowa Hakko Kogyo Co Ltd 6-substituted naphtehalene-2-oxyalkylamines
FR2356422A1 (fr) * 1976-03-01 1978-01-27 Delalande Sa Nouveaux hydroxymethyl-5 oxazolidinone-2, leur procede de preparation et leur application en therapeutique
GB1583653A (en) * 1977-08-06 1981-01-28 Yorkshire Chemicals Ltd Monoazo disperse dyes
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
DE2917569A1 (de) * 1979-04-30 1980-11-13 Basf Ag Verfahren zur herstellung von aromatischen di- und polyurethanen
JPS56131549A (en) * 1980-03-17 1981-10-15 Yasumitsu Tamura Alpha-alkoxyvinyl carbonic acid ester compound, its preparation, and carboalkoxylating and carboaryloxylating agent composed thereof
US4381403A (en) * 1980-03-31 1983-04-26 Atlantic Richfield Company Process for the preparation of N-monosubstituted carbamic acid esters
US4398036A (en) * 1980-05-02 1983-08-09 Atlantic Richfield Company Preparation of N-monosubstituted carbamates
CA1171865A (en) * 1980-06-04 1984-07-31 Alain Lacour N-aryl azolone derivatives, the process for preparing the same and their application in therapeutics
JPS57145853A (en) * 1981-03-06 1982-09-09 Ube Ind Ltd Preparation of aromatic urethane
JPS60241893A (ja) * 1984-05-15 1985-11-30 Kanegafuchi Chem Ind Co Ltd 光学活性（ｓ）―オキサゾリジノン誘導体の製造方法
JPS6115891A (ja) * 1984-07-02 1986-01-23 Taoka Chem Co Ltd 近赤外線吸収金属錯塩化合物
JPS62108870A (ja) * 1985-11-06 1987-05-20 Kanegafuchi Chem Ind Co Ltd 光学活性５−スルホニルオキシメチル−２−オキサゾリジノン誘導体及びその製造方法
JPH0813759B2 (ja) * 1986-09-01 1996-02-14 富士写真フイルム株式会社 アルコキシベンゼン誘導体の製造方法
JPH0723353B2 (ja) * 1987-04-16 1995-03-15 富士写真フイルム株式会社 ５−置換アミノ−１−ヒドロキシ−２−ナフトエ酸アリ−ル化合物
US4985429A (en) * 1987-10-09 1991-01-15 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
JPH082853B2 (ja) * 1988-01-08 1996-01-17 三協化学株式会社 １−オキシ−５−置換アミノ−２−ナフトエ酸の製造法
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5182296A (en) * 1989-10-26 1993-01-26 Tanabe Seiyaky Co., Ltd. Naphthyloxazolidone derivatives

Also Published As

Publication number Publication date
DE69019293T2 (de) 1995-09-07
EP0425209A3 (en) 1992-02-19
KR0128288B1 (ko) 1998-04-02
CA2028440C (en) 1996-11-12
KR910007898A (ko) 1991-05-30
EP0425209B1 (de) 1995-05-10
US5332754A (en) 1994-07-26
EP0425209A2 (de) 1991-05-02
JP2601008B2 (ja) 1997-04-16
ATE122344T1 (de) 1995-05-15
JPH03218367A (ja) 1991-09-25
ES2074544T3 (es) 1995-09-16
CA2028440A1 (en) 1991-04-27
DK0425209T3 (da) 1995-10-09
HK99197A (en) 1997-08-08
US5182296A (en) 1993-01-26

Similar Documents

Publication Publication Date Title
DK0425209T3 (da) Naphtyloxazolidon Derivater
AU1282495A (en) Anthranilic acid derivative
AU5476296A (en) Sulfonamido substituted benzopyran derivatives
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
AU7001996A (en) Novel derivatives of cyclodepsipeptide PF1022 substance
PE34996A1 (es) Nuevo derivado de pirrocarbazol
NO20025035D0 (no) Oksadiazolderivater som har anticancer-effekter
PT1043310E (pt) Derivados de bifenilamidina
AU696948B2 (en) Piperidine derivatives
FI914007A (fi) 4-substituerade dihydropyrido (4,3-d) pyrimidiner som smaertslindrande och lokala inflammationshaemmande medel vid vaord av hudsjukdomar.
DE60228429D1 (de) Medizinische zusammensetzung, die ein 1,3-thiazinderivat enthält
EP1197211A4 (de) Wirkstoffe zur vorbeugung und behandlung von krebs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee